Licensed vaccine
MenQuadfi
FDA-licensed vaccine · Sanofi Pasteur, Inc. · STN 125701
Key facts
| Trade name | MenQuadfi |
|---|---|
| Proper name | Meningococcal (Groups A, C, Y, W) Conjugate Vaccine |
| Manufacturer | Sanofi Pasteur, Inc. |
| Submission tracking number (STN) | 125701 |
| Recent FDA documents | December 17, 2024 Approval Letter - MenQuadfi, September 20, 2024 Approval Letter - MenQuadfi, June 9, 2023 Approval Letter - MenQuadfi, June 16, 2022 Approval Letter - MenQuadfi, October 27, 2021 Approval Letter - MenQuadfi, Approval History, Letters, Reviews, and Related Documents - MenQuadfi, Demographic Subgroup Information – Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi)Refer to Section 1.1 of the Clinical Revie, March 27, 2020 Statistical Review - MenQuadfi, April 22, 2020 Summary Basis for Regulatory Action - MenQuadfi, April 23, 2020 Approval Letter - MenQuadfi, Package Insert and Information for Patients - MenQuadfi |
| FDA page updated | Dec 18, 2024 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 1–9 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: